CLL ASH 2024 Highlights

home / data-dialogue-with-the-oncology-brothers / cll-ash-2024-highlights

Rahul Gosain, MD, MBA; Rohit Gosain, MD, and John Allen, MD, analyze significant developments in chronic lymphocytic leukemia (CLL) treatment, including 5-year SEQUOIA trial outcomes, AMPLIFY survival data, sonrotoclax-zanubrutinib combination therapy, and the emerging role of CAR T-cell therapy, as presented at the 2024 American Society of Hematology (ASH) Annual Meeting.

SEQUOIA Trial: Updates from ASH 2024

EP. 1: SEQUOIA Trial: Updates from ASH 2024

Rahul Gosain, MD;Rohit Gosain, MD;John Allen, MD
December 21st 2024

Experts review the 5-year results of the phase 3 SEQUOIA trial evaluating treatment options for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma at the 66th American Society of Hematology Annual Meeting and Exposition 2024.